Biomaxima (BMX) - Total Liabilities
Based on the latest financial reports, Biomaxima (BMX) has total liabilities worth zł30.50 Million PLN (≈ $8.39 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biomaxima - Total Liabilities Trend (2009–2024)
This chart illustrates how Biomaxima's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Biomaxima to evaluate short-term liquidity relative to the company's equity base.
Biomaxima Competitors by Total Liabilities
The table below lists competitors of Biomaxima ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mitra Pemuda Tbk PT
JK:MTRA
|
Indonesia | Rp207.00 Billion |
|
Globe Textiles (India) Limited
NSE:GLOBE
|
India | Rs2.77 Billion |
|
Megapolitan Developments Tbk
JK:EMDE
|
Indonesia | Rp1.23 Trillion |
|
Star Combo Pharma Ltd
AU:S66
|
Australia | AU$8.30 Million |
|
Karnalyte Resources Inc.
TO:KRN
|
Canada | CA$2.29 Million |
|
Cofidur SA
PA:ALCOF
|
France | €41.36 Million |
|
Kier Group PLC
LSE:KIE
|
UK | GBX3.04 Billion |
|
GreenOak Spain Holdings SOCIMI S.A.
MC:YGO2
|
Spain | €26.09 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Biomaxima's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biomaxima (BMX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomaxima's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomaxima (2009–2024)
The table below shows the annual total liabilities of Biomaxima from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł29.01 Million ≈ $7.98 Million |
+8.21% |
| 2023-12-31 | zł26.81 Million ≈ $7.38 Million |
+22.05% |
| 2022-12-31 | zł21.96 Million ≈ $6.05 Million |
-32.90% |
| 2021-12-31 | zł32.74 Million ≈ $9.01 Million |
+19.08% |
| 2020-12-31 | zł27.49 Million ≈ $7.57 Million |
+2.42% |
| 2019-12-31 | zł26.84 Million ≈ $7.39 Million |
-1.01% |
| 2018-12-31 | zł27.11 Million ≈ $7.46 Million |
+173.06% |
| 2017-12-31 | zł9.93 Million ≈ $2.73 Million |
+50.85% |
| 2016-12-31 | zł6.58 Million ≈ $1.81 Million |
+4.07% |
| 2015-12-31 | zł6.33 Million ≈ $1.74 Million |
-8.73% |
| 2014-12-31 | zł6.93 Million ≈ $1.91 Million |
-15.73% |
| 2013-12-31 | zł8.22 Million ≈ $2.26 Million |
+24.03% |
| 2012-12-31 | zł6.63 Million ≈ $1.82 Million |
+25.67% |
| 2011-12-31 | zł5.28 Million ≈ $1.45 Million |
+39.96% |
| 2010-12-31 | zł3.77 Million ≈ $1.04 Million |
+48.18% |
| 2009-12-31 | zł2.54 Million ≈ $700.15K |
-- |
About Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid… Read more